Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01339897 · ClinicalTrials.gov registry record · Phase 1
A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects
A Phase 1 study, sponsored by Nivalis Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01339897 is a Phase 1 study that has completed, run by Nivalis Therapeutics. The registered enrollment target is 25 participants.
The verdict
NCT01339897, a Phase 1 study, has completed, sponsored by Nivalis Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This Phase 1 study will evaluate multiple doses across a range that has been found to be effective in mouse models of asthma and safe in one Phase 1 clinical trial. It is intended to provide evidence of the tolerability of multiple doses as well as provide information on the Pharmacokinetic (PK) and metabolism of N6022 in humans.
Interventions
- DRUG Placebo
- DRUG 5 mg/N6022
- DRUG 10mg/N6022
- DRUG 20mg/N6022
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-04 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01339897
The ClinicalTrials.gov registry entry for NCT01339897 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nivalis Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01339897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01339897 about?
NCT01339897 is a clinical study titled "A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects". This Phase 1 study will evaluate multiple doses across a range that has been found to be effective in mouse models of asthma and safe in one Phase 1 clinical trial. It is intended to provide evidence of the tolerability of multiple doses as well as provide information on the Pharmacokinetic (PK) and...
What is the current status of trial NCT01339897?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2011-04. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01339897?
The interventions under investigation include: Placebo (DRUG), 5 mg/N6022 (DRUG), 10mg/N6022 (DRUG), 20mg/N6022 (DRUG).
Who is sponsoring clinical trial NCT01339897?
This trial is sponsored by Nivalis Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.